Professor Dagi’s decision to join the
Corporate Update
NurExone expresses its unwavering support for
Despite the adversities, NurExone is fully operational and proactive. Our staff continues to work remotely. We extend sincere appreciation to our investors and partners for their continued warm support.
Our commitment to growth and innovation remains steadfast. We are dedicated to advancing our preparations for clinical trials and expanding to other types of spinal cord injury over time, underscoring our dedication to overcoming spinal cord injury and enhancing the well-being of patients globally.
About
For additional information, please visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.
For more information, please contact:
Dr.
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com
Investment Relation -
Phone: +1 905-347-5569
Email: IR@nurexone.com
Dr.
Investment Relation -
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu
FORWARD-LOOKING STATEMENTS
This press release contains certain “forward-looking statements”, that reflect the Company’s current expectations and projections about its future results. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to the Company’s ExoTherapy drug, ExoPTEN. These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof.
In developing the forward-looking statements in this press release, we have applied several material assumptions, including our ability to retain key personnel, our ability to continue investing in research and development, our ability to secure available funding and to continue as a going concern, the general business and economic conditions of the industries and countries in which we operate, that the Company’s operations in
Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the Company’s early stage of development, lack of revenues to date, government regulation, market acceptance for its products, rapid technological change, dependence on key personnel, protection of the Company’s intellectual property, dependence on the Company’s strategic partners, the effect of the Israel-Hamas War on the Company’s operations and the risks discussed under the heading “Risk Factors” on pages 29 to 36 of the Company’s Annual Information Form dated
Neither
Source:
2023 GlobeNewswire, Inc., source